Clinical implication of quantitative flow ratio to predict clinical events after drug-coated balloon angioplasty in patients with in-stent restenosis

Jiani Tang MD¹ | Hanjing Hou MD² | Jiapeng Chu MD¹ | Fei Chen MD¹ | Yian Yao MD¹ | Yanhua Gao MD¹ | Zi Ye MD¹ | Shaowei Zhuang MD² | Yan Lai MD¹ | Xuebo Liu MD¹

¹Department of Cardiology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China
²Department of Cardiology, Seventh People’s Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Correspondence
Xuebo Liu and Yan Lai, No.389, Xincun Rd, Putuo District, Shanghai 200065, China. Email: liuxuebo70@126.com and laiyanb@163.com

Funding information
National Natural Science Foundation of China, Grant/Award Number: 81670403; Shanghai Municipal Health Commission, Grant/Award Number: 2019LJ10; Shanghai Science and Technology Committee, Grant/Award Numbers: 18411950300, 19411963200, 19XD1403300

Abstract
Background: The association between the quantitative flow ratio (QFR) and adverse events after drug-coated balloon (DCB) angioplasty for in-stent restenosis (ISR) lesions has not been investigated.
Hypothesis: Post-procedural QFR is related to adverse events in patients undergoing DCB angioplasty for ISR lesions.
Methods: This retrospective study included data from patients undergoing DCB angioplasty for drug-eluting stent (DES) ISR between January 2016 and February 2019. The QFR was measured at baseline and after DCB angioplasty. The endpoint was the vessel-oriented composite endpoint (VOCE), defined as a composite of cardiac death, vessel-related myocardial infarction, and ischemia-driven target vessel revascularization.
Results: Overall, 177 patients with 185 DES-ISR lesions were included. During 1-year follow-up, 27 VOCEs occurred in 26 patients. The area under curve (AUC) of the post-procedural QFR was statistically greater than that of the in-stent percent diameter stenosis (0.77, 95% confidence interval [CI] 0.67–0.87 vs. 0.64, 95% CI 0.53–0.75; p = .032). Final QFR cutoff of 0.94 has the best predictive accuracy for VOCE. A QFR > 0.94 was associated with a lower risk of VOCE compared to a QFR ≤ 0.94 (log-rank test, p < .0001). Survival analysis using the multivariable Cox model showed that a post-procedural QFR ≤ 0.94 was an independent predictor of 1-year VOCE (hazard ratio 6.53, 95% CI 2.70–15.8, p < .001).
Conclusions: A lower QFR value was associated with worse clinical outcomes at 1 year after DCB angioplasty for DES-ISR.

Keywords
drug-coated balloon, percutaneous coronary intervention, quantitative flow ratio
INTRODUCTION

Although drug-eluting stents (DES) effectively inhibit neointimal proliferation and markedly reduce the incidence of in-stent restenosis (ISR), recurrent ISR requiring repeat revascularization still occurs after DES implantation, and treatment of DES-ISR remains a major challenge in the percutaneous coronary intervention (PCI) field. Drug-coated balloons (DCB) are semi-compliant balloons covered with antiproliferative drugs such as lipophilic paclitaxel and have been proposed as an alternative to DES. During balloon inflation, the lipophilic paclitaxel is delivered to the vessel wall surface providing an antiproliferative effect and preventing neointimal hyperplasia without additional metallic layers. In this respect, several clinical trials support the efficacy of DCB in the treatment of ISR.

The fractional flow reserve (FFR) is the gold standard to assess the physiological severity of coronary stenosis. Several trials have reported an inverse relationship between the post-interventional FFR and the risk of subsequent adverse events. Additionally, the FFR has been identified as a reference standard to ascertain functional ISR severity. Quantitative flow ratio (QFR), a novel technique for the rapid computation of FFR from coronary angiography without the use of pressure wires or hyperemic agents, has good correlation with FFR and proven clinical value in guiding pre- and post-PCI management. Although the diagnostic performance of the QFR in assessing ISR lesions using FFR as a reference standard has been recently investigated, its utility in the context of DCB angioplasty remains unknown. In the present study, we aimed to perform the first validation of the QFR as a tool to predict events in patients with ISR treated with DCB.

MATERIALS AND METHODS

Study design and population

This was a retrospective analysis of consecutive patients with at least one ISR lesion who underwent DCB angioplasty between January 2016 and February 2019 from two centers in Shanghai, China. Exclusion criteria were a TIMI flow grade <3 at baseline or after DCB angioplasty, ST-segment elevation myocardial infarction (MI), major procedural complications requiring DES implantation, and significant left main ISR lesion or inadequate angiographic image quality limiting the QFR computation. The study protocol complied with the Declaration of Helsinki and was approved by the ethics committee at each participating institution.

PCI procedures and angiographic characteristics

ISR lesions were treated using paclitaxel-coated balloons (Sequent Please, B Braun Melungeon, Germany). All patients were pretreated with aspirin and a P2Y12 inhibitor (i.e., clopidogrel or ticagrelor). The DCB size was selected based on the length of the target lesion and the diameter of the previously used stents. The details of the PCI strategy and intravascular imaging utilization were left entirely at the operators’ discretion. The ISR was classified as focal (type I, <10 mm in length), diffuse (type II, >10 mm in length) and proliferative (type III, >10 mm in length and extending outside the stent).

Quantitative coronary angiography analyses were performed before and after DCB angioplasty using an offline computerized quantitative coronary angiographic system (CAAS system; Pie Medical Instruments, Maastricht, The Netherlands). The following parameters were measured: reference vessel diameter (RVD), minimal lumen diameter (MLD), and percent diameter stenosis (%DS). Measurements of the stented area were obtained shoulder-to-shoulder (in-stent) and including the total stented area plus 5 mm proximally and distally (in-segment). The acute lumen gain was calculated as the difference between post- and pre-procedural MLD.

Off-line QFR assessment

Off-line QFR was performed by experienced analysts certified for the use of the QFR system software (AngioPlus, Pulse Medical Imaging Technology, Shanghai Co. Ltd., Shanghai, China). For QFR computations, two angiographic projections, at least 25° apart, were transferred to the QFR system, and three-dimensional reconstruction of the interrogated vessel without its side branches was performed as described elsewhere. The lumen contour was estimated automatically. Manual correction was performed in cases of suboptimal angiographic image quality based on a standard operation procedure. A contrast flow model incorporating contrast flow velocity based on the frame count method was used for QFR computations. Three-dimensional quantitative coronary analysis data were readily available. Subsequently, the QFR was computed. Case example is provided in Figure 1.

Follow-up and outcome definition

In the present study, we investigated the relationship between the post-procedural QFR and clinical outcomes at the vessel level. Clinical follow-up data derived from clinical visits, telephone interviews, and from hospital records of any readmissions.

The primary endpoint of this study was the vessel-oriented composite endpoint (VOCE) at 1 year, defined as the composite of cardiac death, vessel-related MI, or ischemia-driven target vessel revascularization (TVR). The secondary endpoints were the individual components of the VOCE.

Any death of unknown cause was assumed as due to cardiac cause. The diagnosis of MI was based on the fourth universal definition of MI, which requires a combination of symptoms, electrocardiographic changes, and significant increase in troponin. When the identification of the culprit vessel was not possible, the endpoint was evaluated considering each vessel treated with DCB. Ischemia-driven
TVR was defined as any repeated revascularization of the target vessel by either PCI or coronary artery bypass grafting (CABG) in the presence of a lesion with a %DS >50%, and with at least one of the following: (i) recurrence of angina, (ii) positive non-invasive test, and (iii) positive invasive physiologic test. All angiograms of patients who underwent TVR were reviewed to identify the target lesion revascularization.

2.5 Statistical analysis

Continuous variables are presented as the median with interquartile range and compared between groups using the Mann–Whitney U test. Categorical variables are summarized as frequencies and proportions and compared using Pearson’s chi-square or Fisher’s exact test. Intraclass correlation coefficient

FIGURE 1 Case example of reconstructed 3-D QCA and measured QFR. QFR calculation was based on the 3D-QCA reconstructed from two angiographic projections with angles ≥25° apart and 3D reconstruction of the interrogated vessel without its side branches was performed. (A) Pre-procedural angiographic image shows a ISR lesion, and QFR was 0.70. Final angiography showed minimal residual stenosis after DCB treatment, and QFR was 0.96. Red arrows indicate the target ISR lesion. DCB, drug-coated balloon; ISR, in-stent restenosis; QCA, quantitative coronary angiography; QFR, quantitative flow ratio.
|                          | VOCE \(n = 27\) | Non-VOCE \(n = 158\) | \(p\) value |
|--------------------------|------------------|----------------------|-------------|
| **Target artery**        |                  |                      |             |
| Left anterior descending, n (%) | 19 (70.4)        | 74 (46.8)            | .077        |
| Left circumflex, n (%)    | 3 (11.1)         | 34 (21.5)            |             |
| Right coronary, n (%)     | 5 (18.5)         | 50 (31.6)            |             |
| **Index stent type**     |                  |                      |             |
| Everolimus-eluting, n (%) | 9 (33.3)         | 36 (22.8)            | .238        |
| Sirolimus-eluting, n (%)  | 11 (40.7)        | 89 (56.3)            | .133        |
| Zotarolimus-eluting, n (%)| 5 (18.5)         | 21 (13.3)            | .673        |
| Unknown, n (%)            | 2 (7.4)          | 12 (7.6)             | >.999       |
| **Moderate or severe calcification, n (%)** | 5 (18.5)   | 18 (11.4)            | .471        |
| **Bifurcation lesion, n (%)** | 4 (14.8)    | 40 (25.3)            | .236        |
| **IVUS use, n (%)**       | 6 (22.2)         | 34 (21.5)            | .936        |
| **Restenosis classification** |                |                      |             |
| Focal, n (%)              | 11 (40.7)        | 65 (41.1)            | .969        |
| Diffuse, n (%)            | 9 (33.3)         | 61 (38.6)            | .602        |
| Proliferative, n (%)      | 7 (25.9)         | 32 (20.3)            | .504        |
| **Edge-ISR, n (%)**       | 2 (7.4)          | 20 (12.7)            | .747        |
| **Pre-procedural QCA**    |                  |                      |             |
| Reference vessel diameter, mm | 2.7 (2.4–2.8)   | 2.7 (2.4–3.0)        | .325        |
| Minimal lumen diameter, mm | 0.9 (0.7–1.1)   | 0.9 (0.7–1.2)        | .672        |
| Diameter stenosis, %      | 64.0 (56.0–73.4) | 66.7 (56.1–75.0)     | .843        |
| Lesion length, mm         | 20.0 (10.4–31.0) | 18.6 (10.0–24.9)     | .227        |
| **Post-procedural QCA (in-segment)** |         |                      |             |
| Minimal lumen diameter, mm | 1.6 (1.5–2.0)   | 1.9 (1.8–2.2)        | .008        |
| Diameter stenosis, %      | 34.5 (30.9–40.0) | 28.3 (23.4–34.2)     | .003        |
| Acute lumen gain, mm      | 0.8 (0.6–1.1)    | 1.0 (0.7–1.3)        | .021        |
| **Post-procedural QCA (in-stent)** |           |                      |             |
| Minimal lumen diameter, mm | 1.7 (1.5–2.1)   | 2.0 (1.8–2.2)        | .017        |
| Diameter stenosis, %      | 31.0 (25.9–36.0) | 25.1 (21.4–32.2)     | .018        |
| Acute lumen gain, mm      | 0.9 (0.7–1.2)    | 1.0 (0.8–1.3)        | .238        |
| **Physiological results** |                  |                      |             |
| Pre-procedural QFR        | 0.67 (0.52–0.76) | 0.71 (0.61–0.78)     | .084        |
| Pre-procedural QFR > 0.80, n (%) | 0 (0.0)     | 6 (3.8)              | .595        |
| Post-procedural QFR       | 0.91 (0.83–0.95) | 0.98 (0.95–0.99)     | <.001       |
| Post-procedural QFR ≤0.80, n (%) | 5 (18.5)   | 6 (3.8)              | .011        |
| **Balloon pre-dilation**  |                  |                      |             |
| Diameter, mm              | 3.0 (2.5–3.0)    | 2.75 (2.5–3.0)       | .550        |
| Length, mm                | 15 (15–15)       | 15 (15–15)           | .935        |
| Pressure, atm             | 15 (14–16)       | 14 (12–18)           | .934        |
| Inflation time, s         | 5 (5–10)         | 5 (5–10)             | .767        |
| **Cutting balloon**       |                  |                      |             |
| Diameter, mm              | 2.8 (2.6–2.9)    | 3.0 (2.5–3.0)        | .583        |
| Length, mm                | 10 (10–11.5)     | 10 (10–10)           | .650        |
| Pressure, atm             | 8 (8–10)         | 10 (8–12)            | .678        |
| Inflation time, s         | 5 (5–5)          | 5 (5–10)             | .303        |
analysis was performed to evaluate inter- and intra-observer agreement. Receiver operator characteristic curve (ROC) analysis was performed to determine the optimal post-procedural QFR cut-off value to predict VOCE occurrence. ROC and the area under curve (AUC) were performed to assess and compare the ability of the post-procedural QFR and in-stent %DS for predicting adverse outcomes using the DeLong method. Cox multivariable analysis was performed to determine independent predictors of the VOCE. We selected the variables by means of the LASSO (Least Absolute Shrinkage and Selection Operator) method. Hazard ratios (HRs) with corresponding 95% confidence interval (CI) were provided. The Kaplan–Meier method was used to demonstrate the timing of events during follow-up in relation to the post-procedural QFR value, and the log-rank test was applied to compare survival curves among groups. A significant level was defined when \( p < .05 \). All analyses were performed using R software, version 3.4.3. (R Foundation for Statistical Computing, Vienna, Austria).

### 3 | RESULTS

#### 3.1 | Patient characteristics

The flow chart of this study was shown in Figure S1. During the study period, a total of 177 patients with 185 DES-ISR lesions undergoing

| VOCE \( (n = 27) \) | Non-VOCE \( (n = 158) \) | \( p \) value |
|-----------------|-----------------|----------|
| **DCB** | | |
| No. of DCB used >1 | 3 (11.1) | 14 (8.9) | .719 |
| Diameter, mm | 3.0 (2.6–3.0) | 3.0 (2.5–3.0) | .953 |
| Length, mm | 26 (20–28) | 20 (20–26) | .703 |
| Inflation pressure, atm | 8 (7–8) | 8 (7–8.75) | .796 |
| Inflation time, s | 60 (60–60) | 60 (60–60) | .553 |
| Balloon-to-artery ratio | 1.08 (1.05–1.15) | 1.10 (0.97–1.19) | .930 |

Note: Values are shown as median (25th–75th percentile) or number (%). \( p \) values < .05 are in italics.

Abbreviations: DCB, drug-coated balloon; ISR, in-stent restenosis; IVUS, intravascular ultrasound; QCA, quantitative coronary angiography; QFR, quantitative flow ratio.
DCB angioplasty were eligible for inclusion in this study. The baseline patient characteristics are outlined in Table S1. The median age was 68 (62–75) years and male sex was predominant (81%). The median interval from the latest DES implantation to the DCB angioplasty for ISR lesion was 389 (230–1725) days. Apart from a higher rate of diabetes mellitus in the VOCE group (69.2% vs. 43.7%, p = .016), there were no significant differences in age, gender, clinical risk factors, laboratory results and clinical diagnosis between patients with or without VOCE.

Characteristics of the lesions and procedures are shown in Table 1. Of 185 vessels evaluated, 93 (50.3%) corresponded to left anterior descending arteries, 37 (20%) to left circumflex arteries, and 55 (29.7%) to right coronary arteries. There were no significant differences in the index DES type, lesion characteristics, restenosis classification, or rate of edge-ISR. The pre-procedural lesion lengths, RVD, MLD, %DS, and rate of cutting balloon use or DCB use beyond 1 were similar in both groups.

Regarding post-procedural changes, while the acute lumen gain of the in-stent segment behaved similarly between groups, the %DS and MLD were significantly higher and smaller, respectively, in vessels with VOCE than in vessels without VOCE (31.0% [25.9–36.0%] vs. 25.1% [21.4–32.2%], p = .018; 1.7 mm [1.5–2.1 mm] vs. 2.0 mm [1.8–2.2 mm], p = .017; respectively). With respect to the in-segment post-procedural quantitative coronary angiography analysis, vessels with VOCE showed a significantly larger %DS (34.5% [30.9–40.0%] vs. 28.3% [23.4–34.2%], p = .003), smaller MLD (1.6 mm [1.5–2.0 mm] vs. 1.9 mm [1.8–2.2 mm], p = .008), and smaller acute lumen gain (0.8 mm [0.6–1.1 mm] vs. 1.0 mm [0.7–1.3 mm], p = .021) than vessels without VOCE.

Before and after DCB angioplasty, the intraclass correlation coefficients for inter-observer variability of QFR was 0.93 (95% CI, 0.91–0.95) and 0.94 (95% CI, 0.92–0.95), respectively. Agreement in QFR was also excellent for the same analysts (Pre-procedure: 0.95 [95% CI, 0.92–0.97] and post-procedural: 0.94 [95% CI, 0.92–0.96]).

The distribution of individual QFRs before and after DCB angioplasty is reported in Figure S2A. While there was no significant difference between the two groups with respect to the pre-procedural QFR (0.67 [0.52–0.76] vs. 0.71 [0.61–0.78], p = .084), vessels with VOCE had a significantly lower post-procedural QFR than vessels without VOCE (0.91 [0.83–0.95] vs. 0.98 [0.95–0.99], p < .001).

### 3.2 Definition of a potential cutoff value

The occurrence of the VOCE stratified according to the post-procedural QFR is depicted in Figure S2B. ROC analysis showed that the optimal post-procedural QFR cut-off value for predicting the VOCE was 0.94, with a sensitivity of 74% and specificity of 75%. The ROC curves for the in-stent %DS and post-procedural QFR are shown in Figure 2(A). In the direct comparison with in-stent %DS, QFR showed better ability to discriminate vessels at risk of the VOCE (AUCs 0.77 [95% CI 0.67–0.87] vs. 0.64 [95% CI 0.53–0.75], p = .032).

### 3.3 Clinical outcomes

Clinical follow-up was completed in all patients. The median patient follow-up was 364 days (355–369 days). Clinical outcomes at 12 months are summarized in Table 2. Patients who achieved a post-procedural QFR > 0.94 had significantly less VOCEs than those with values ≤0.94 (5.6% vs. 33.9%, p < .001); this difference was mostly driven by a higher rate of TVR (4.8% vs. 32.2%, p < .001). Two patients presented more than one event during the follow-up; both developed target vessel MI and underwent target lesion revascularization. One patient with a post-procedural QFR ≤ 0.94 died of cardiac

### Table 2. Clinical outcomes stratified by the cutoff value of post-procedure QFR at vessel level

| outcome                  | QFR < 0.94 (n = 59) | QFR > 0.94 (n = 126) | p value |
|--------------------------|---------------------|---------------------|---------|
| Death                    | 2 (3.4)             | 1 (0.8)             | .491    |
| Cardiac death            | 1 (1.7)             | 0 (0.0)             | >.999   |
| Myocardial infarction    | 3 (5.1)             | 1 (0.8)             | .072    |
| Target vessel MI         | 2 (3.4)             | 1 (0.8)             | .179    |
| Target vessel revascularization | 19 (32.2) | 6 (4.8) | < .001 |
| Coronary angioplasty     | 17 (28.8)           | 5 (4.0)             | < .001 |
| Coronary surgery         | 2 (3.4)             | 1 (0.8)             | .317    |
| Target lesion revascularization | 18 (30.5) | 6 (4.8) | < .001 |
| VOCE                     | 20 (33.9)           | 7 (5.6)             | < .001 |

Note: patients with >1 event are counted only once for the composite clinical endpoint, although each event is listed separately in the corresponding category. p values <.05 are in italics.

### Table 3. Multivariable cox regression analyses for predictors of VOCE (n = 27)

| predictor                      | HR (95% CI) | p value |
|--------------------------------|-------------|---------|
| Model 1                        |             |         |
| Post-procedural QFR ≤ 0.94     | 6.53 (2.70–15.8) | < .001 |
| Diabetes mellitus              | 2.32 (1.04–5.19) | .040   |
| Diameter stenosis (Post-procedural in-stent) | 1.03 (0.99–1.07) | .196   |
| Model 2                        |             |         |
| Post-procedural QFR per 0.1 increase | 0.36 (0.22–0.59) | < .001 |
| Diabetes mellitus              | 1.76 (0.77–4.05) | .180   |
| Diameter stenosis (Post-procedural in-stent) | 1.02 (0.99–1.07) | .124   |

Note: Models after LASSO (Least Absolute Shrinkage and Selection Operator) variable selection method. p values <.05 are in italics.

Abbreviations: CI, confidence interval; HR, hazard ratio; QFR, quantitative flow ratio; VOCE, vessel-oriented composite endpoint.
cause. No cardiac death occurred in patient with a post-procedur-
al QFR > 0.94.

Repeat revascularization was performed in 19 (32.2%) vessels
with a post-procedural QFR ≤0.94 due to recurrent ISR; two of these
cases underwent CABG. In turn, six (4.8%) vessels with final
QFR > 0.94 required reinterventions: five underwent coronary ste-
tenting and one CABG. The Kaplan–Meier curves depicting the oc-
currence of the VOCE within the study period are shown in Figure 2(B).
Lower post-procedural QFR values were significantly associated with
a higher incidence of the VOCE (p < .0001).

Variables predicting VOCE obtained after penalization using
LASSO method included following three variables: post-procedural
QFR ≤0.94; diabetes mellitus; post-procedural in-stent %DS. Multi-
variable Cox proportional hazards analyses revealed that, after adjusting
for potential confounding factors, a post-procedural QFR of ≤0.94 was
associated with an over 6-fold increase in the risk of the VOCE (hazard
ratio [HR] 6.53, 95% CI 2.70–15.8; p < .0001) (Table 3). When consid-
ering the post-procedural QFR as a continuous variable, post-
procedural QFR (each 0.1 increase) was associated with lower risk of
VOCE in multivariable adjusted analysis (HR 0.36; 95% CI 0.22–0.59,
p < .001) (Table 3).

4  |  DISCUSSION

The main findings of this study are as follows: (1) a low QFR after
DCB angioplasty in DES-ISR lesions was an independent predictor of
adverse clinical events during a 1-year follow up; (2) compared with
the in-stent %DS, the QFR has a better ability to predict vessel-
related clinical outcomes after DCB angioplasty.

To the best of our knowledge, this is the first study to describe
the utility of the QFR to predict clinical events after DCB angioplasty
for ISR lesions. Our results showed that the QFR measured immedi-
ately after the procedure had an inverse relationship with future cli-
nical events. Notably, the pre-procedure QFR had no association with
outcomes. Conceptually, interventions destined to increase the post-
procedural QFR may be able to improve long-term outcomes.

Although the choice of the PCI strategy has routinely been based
on angiographic findings, these have limited efficacy to predict imme-
diate physiological results or clinical outcomes of coronary stenting.23
As a result, the concept of functional optimization of PCI results has
been explored for a long time. In this regard, a previous study found a
graded relationship between post-PCI FFR and major adverse cardio-
vascular events.24 With respect to analyses of the final functional
results after DES implantation, a large meta-analysis performed by
Johnson et al25 showed an inverse relationship between post-PCI FFR
and the rate of vessel-related adverse outcomes. These results
suggest that post-PCI physiological assessments can predict adverse
clinical outcomes by identifying residual disease across the stented
and adjacent segments. For the determination of procedural success,
angiographic residual %DS has been commonly used in clinical prac-
tice, but its limitation is well known. In this study, we compared the
prognostic ability of QFR and in-stent stenosis severity after DCB
angioplasty on clinical events, and we found that the former had a
better performance.

The optimal treatment strategy for DES-ISR remains undefined.
Based on clinical trials that support its efficacy, angioplasty with DCB
is recommended for the treatment of ISR in the European clinical
practice guidelines (Class I, Level of Evidence: A).26 Prospective
studies have confirmed the utility of the FFR to guide clinical decision
making in ISR treatment and suggest that revascularization can be
safely deferred in patients with an FFR > 0.75.27 Recent studies found
that FFR-guided DCB treatment of de novo lesions appeared feasible
and safe in stable patients.28 Whether the use of post-procedural
physiological assessments could be expanded to angioplasty with
DCB for ISR lesions had not been sufficiently studied to date.

Nevertheless, while evidence supporting the utility of FFR has
been mounting, FFR is still largely underutilized in clinical practice.29
Reasons for this may include the high equipment and drug costs, and
the risk of related complications. Progress in angiography-derived FFR
such as the QFR can reduce these limitations by calculation of func-
tional parameters in a simpler and rapid way. A recent study demon-
strated substantial applicability of the QFR in functional assessment
of ISR lesions, using FFR as reference standard.16 Furthermore, Li
et al.30 investigated the functional results following DCB or DES treat-
ment in small-vessel disease and demonstrated that assessing the
QFR in small coronary arteries was feasible. Therefore, these studies
suggest that the QFR is not only a promising tool in assessing clinical
results of stenting but can also be applied to assess the efficacy of
DCB in the treatment of ISR and de novo lesions.

Unlike pre-procedural functional assessment, where parameters to
determine an ischemia-causing stenosis are clearly defined, post-
procedural cutoff values vary widely due to multiple factors, including
the population studied, lesion and procedural characteristics, the presence
of multivessel disease and the incidence of clinical events.11,12,14 Recently
in the HAWKEYE study, Biscaglia et al.14 reported that post-PCI QFR lower
than 0.90 was associated with a higher rate of VOCE. Kogame et al.15
demonstrated that the cutoff value of post-PCI QFR was 0.91 in relatively
high-risk patients with de novo 3-vessel disease. Our previous study found
that post-PCI QFR ≥0.91 was associated with a lower rate of VOCE.31 In
our present study, we were able to identify a threshold for post-procedural
QFR (0.94) that could be used to discriminate ISR lesions treated by DCB
angioplasty at a higher risk of clinical events. In addition to the utility of this
dichotomous approach, results of Cox proportional hazards regression
analysis revealed that progressive decreases in the QFR were also related
to a higher risk of adverse clinical outcomes at 1-year follow-up.

There are a number of limitations in the current study. First, the
small sample size precluded subgroup analysis. Second, the rigorous
inclusion and exclusion criteria have theoretically introduced a selec-
tion bias; thus, our conclusions cannot be extrapolated to the
excluded patients. Third, the determination of the threshold value was
based solely on our clinical data; the optimal values may vary by dif-
ferent populations. Additional studies are needed to validate the cut-
off value derived in our study. Finally, although a lower QFR was
associated with a higher rate of adverse outcomes, this study was not
able to evaluate the clinical impact of interventions to improve
suboptimal post-procedural functional results. Large randomized controlled trials are necessary to address this question.

5 | CONCLUSION

A low post-procedural QFR was associated with poor clinical outcomes within 1 year after DCB angioplasty for DES-ISR. Compared with the post-procedural in-stent %DS, the QFR may be superior to predict vessel-related clinical outcomes. Future studies should be conducted to confirm our results and evaluate the utility of the QFR to guide therapeutic decisions in ISR lesions.

CONFLICT OF INTEREST

The authors have no potential conflict of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Xuebo Liu https://orcid.org/0000-0001-9985-8960

REFERENCES

1. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998-1008.

2. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.

3. Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63:2659-2673.

4. Alfonso F, Scheller B. State of the art: balloon catheter technologies-drug-coated balloon. EuroIntervention. 2017;13:680-695.

5. Haybar H, Shahzadi S, Rezaeevyan H, Shirzad R, Saki N. Endothelial cells: from dysfunction mechanism to pharmacological effect in cardiovascular disease. Cardiovasc Toxicol. 2019;19:13-22.

6. Gobic D, Tomulic V, Lulic D, et al. Drug-coated balloon versus drug-eluting stent in primary percutaneous coronary intervention: a feasibility study. Am J Med Sci. 2017;354:553-560.

7. Alfonso F, Perez-Vizcayno MJ, Garcia Del Blanco B, et al. Long-term results of everolimus-eluting stents versus drug-eluting balloons in patients with bare-metal in-stent restenosis: 3-year follow-up of the RIBS V clinical trial. JACC Cardiovasc Interv. 2016;9:1246-1255.

8. Scheller B, Hrehlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355:2113-2124.

9. De Bruyne B, Pijs NH, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991-1001.

10. Kasula S, Agarwal SK, Hacioglu Y, et al. Clinical and prognostic value of poststenting fractional flow reserve in acute coronary syndromes. Heart. 2016;102:1988-1994.

11. Rimac G, Fearon WF, De Bruyne B, et al. Clinical value of post- percutaneous coronary intervention fractional flow reserve value: a systematic review and meta-analysis. Am Heart J. 2017;183:1-9.

12. Nam CW, Rha SW, Koo BK, et al. Usefulness of coronary pressure measurement for functional evaluation of drug-eluting stent restenosis. Am J Cardiol. 2011;107:1783-1786.

13. Tu S, Westra J, Yang J, et al. Diagnostic accuracy of fast computational approaches to derive fractional flow reserve from diagnostic coronary angiography: the international multicenter FAVOR pilot study. JACC Cardiovasc Interv. 2016;9:2024-2035.

14. Biscaglia S, Tebaldi M, Brugaletta S, et al. Prognostic value of QFR measured immediately after successful stent implantation: the international multicenter prospective HAWKEYE study. JACC Cardiovasc Interv. 2019;12:2079-2088.

15. Kogame N, Takahashi K, Tomanik M, et al. Clinical implication of quantitative flow ratio after percutaneous coronary intervention for 3-vessel disease. JACC Cardiovasc Interv. 2019;12:2064-2075.

16. Liontou C, Mejia-Renteria H, Lauri F, et al. Functional assessment of in-stent restenosis with quantitative flow ratio. EuroIntervention. 2019; Online Ahead of Print.

17. Mehra R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100:1872-1878.

18. Xu B, Tu S, Qiao S, et al. Diagnostic accuracy of angiography-based quantitative flow ratio measurements for online assessment of coronary stenosis. J Am Coll Cardiol. 2017;70:3077-3087.

19. Westra J, Andersen BK, Campo G, et al. Diagnostic performance of in-procedure angiography-derived quantitative flow reserve compared to pressure-derived fractional flow reserve: the FAVOR II Europe-Japan study. J Am Heart Assoc. 2018;7:e009603.

20. Thygensen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction. Eur Heart J. 2019;40:237-269.

21. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:857-865.

22. Tibshirani R. The lasso method for variable selection in the cox model. Stat Med. 1997;16:385-395.

23. Meijboom WB, Van Mieghem CA, van Pelt N, et al. Comprehensive assessment of coronary artery stenoses: computed tomography coronary angiography versus conventional coronary angiography and correlation with fractional flow reserve in patients with stable angiina. J Am Coll Cardiol. 2008;52:636-643.

24. Pijs NH, Klauss V, Siebert U, et al. Coronary pressure measurement after stenting predicts adverse events at follow-up: a multicenter registry. Circulation. 2002;105:2950-2956.

25. Johnson NP, Toth GG, Lai D, et al. Prognostic value of fractional flow reserve: linking physiologic severity to clinical outcomes. J Am Coll Cardiol. 2014;64:1641-1654.

26. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40:87-165.

27. Lopez-Palop R, Pinar E, Lozano I, Saura D, Picó F, Valdés M. Utility of the fractional flow reserve in the evaluation of angiographically moderate in-stent restenosis. Eur Heart J. 2004;25:2040-2047.

28. Poerner TC, Duderstadt C, Goebel B, Kretzschmar D, Figulla HR, Otto S. Fractional flow reserve-guided coronary angioplasty using paclitaxel-coated balloons without stent implantation: feasibility, safety and 6-month results by angiography and optical coherence tomography. Clin Res Cardiol. 2017;106:18-27.

29. Tebaldi M, Biscaglia S, Fineschi M, et al. Evolving routine standards in invasive hemodynamic assessment of coronary stenosis: the Nationwide Italian SICI-GISE cross-sectional ERIS study. JACC Cardiovasc Interv. 2018;11:1482-1491.

30. Li L, Guan C, Meng S, et al. Short- and long-term functional results following drug-coated balloons versus drug-eluting stents in small coronary vessels: the RESTORE quantitative flow ratio study. Int J Cardiol. 2021;327:45-51.
31. Tang J, Chu J, Hou H, et al. Clinical implication of QFR in patients with ST-segment elevation myocardial infarction after drug-eluting stent implantation. *Int J Cardiovasc Imaging*. 2021;37:755-766.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

---

**How to cite this article:** Tang J, Hou H, Chu J, et al. Clinical implication of quantitative flow ratio to predict clinical events after drug-coated balloon angioplasty in patients with in-stent restenosis. *Clin Cardiol*. 2021;44(7):978-986. [https://doi.org/10.1002/clc.23630](https://doi.org/10.1002/clc.23630)